Grail says FDA advisory panel meets Sept. 23 on Galleri test PMA review
GRAL•FDA advisory panel review scheduled for Sept. 23
Grail says it faces an FDA advisory committee review on Sept. 23, 2026, for its Galleri multi-cancer early detection blood test PMA.
- The PMA was submitted on Jan. 29, 2026.
- The FDA granted Galleri Breakthrough Device designation in 2018.
Related News
Vistagen Therapeutics Says Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
VTGN•
Eldorado Gold Corporation <ELD.TO>: BofA Global Research raises to Buy from Underperform; raises price objective to C$77 from C$45
EGO•
